PURPOSE: Our aim was to investigate the efficacy and prognostic factors of intraocular injections of bevacizumab as needed in @entity1 with @entity1103 secondary to @entity2994 ( @entity2994 ). METHODS: This is a retrospective study including 28 eyes of 27 consecutive @entity1 with @entity1103 due to @entity2994 and followed for at least 6 months. The mean age of the @entity1 was 66.3 years. The @entity1 underwent an intravitreal injection of bevacizumab (1.25 mg) at the initial visit. Retreatments were performed when @entity1103 was persistent or worsened (as-needed regimen). The primary outcome measure was the mean change in best-corrected visual acuity (BCVA). The change in central retinal thickness (CRT) was evaluated as the secondary outcome. Finally, the factors useful for predicting BCVA outcome were determined. RESULTS: The mean number of injections was 1.8 over a period of 6 months. The mean BCVA (logarithm of minimum angle of resolution) was significantly improved at 1 (-0.097), 3 (-0.14), and 6 months (-0.25) after the initial injection (P<0.05, <0.01, and <0.001, respectively). The mean CRT was also improved significantly at 1 (-250.4), 3 (-150.0), and 6 months (-187.2) (P<0.001 each). Earlier treatment and better improvement in BCVA at 1 month after the initial treatment were the prognostic factors significantly associated with better visual outcomes at 6 months (P=0.047 and 0.029, respectively). CONCLUSION: Intravitreal injection of bevacizumab as needed significantly improved visual acuity and @entity1103 in @entity2994 @entity1 . Time before the treatment and early response to the treatment were important factors for the visual outcome.

Efficacy and visual prognostic factors of intravitreal bevacizumab as needed for @entity1103 secondary to XXXX .

@entity1 :: ('9606', 'Species') :: ['patients'] @entity2994 :: ('MESH:D012170', 'Disease') :: ['central retinal vein occlusion', 'CRVO'] @entity1103 :: ('MESH:D008269', 'Disease') :: ['macular edema']
@entity2994 :: (MESH:D012170,Disease) :: ['central retinal vein occlusion']
